2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
| Title | Journal |
|---|---|
| Mirabegron: potential off target effects and uses beyond the bladder. | British journal of pharmacology 20181101 |
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. | Expert opinion on drug metabolism & toxicology 20130501 |
| Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder. | International journal of clinical pharmacology and therapeutics 20121101 |
| Use of mirabegron in treating overactive bladder. | International urogynecology journal 20121001 |
| Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist. | Xenobiotica; the fate of foreign compounds in biological systems 20121001 |
| Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. | Clinical therapeutics 20121001 |
| Emerging therapies: what's new is old and what's old is new. | The Canadian journal of urology 20121001 |
| An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120815 |
| Overactive bladder, under scrutiny, gets a new treatment. | Nature medicine 20120801 |
| Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. | BJU international 20120701 |
| Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. | BJU international 20120701 |
| [Pharmacological and clinical profile of mirabegron (Betanis(®)): a new therapeutic agent for overactive bladder]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20120501 |
| Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies. | Postgraduate medicine 20120501 |
| Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management. | Postgraduate medicine 20120501 |
| Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. | Drug metabolism and disposition: the biological fate of chemicals 20120401 |
| Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120301 |
| Mirabegron for the treatment of overactive bladder. | Drugs of today (Barcelona, Spain : 1998) 20120101 |
| Mirabegron: a safety review. | Expert opinion on drug safety 20110301 |
| Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. | Korean journal of urology 20101201 |
| Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. | IDrugs : the investigational drugs journal 20101001 |
| Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges. | Naunyn-Schmiedeberg's archives of pharmacology 20100801 |
| Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder. | World journal of urology 20091201 |
| Pharmacotherapy of the overactive bladder. | Discovery medicine 20091001 |
| Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study. | European urology 20090701 |
| Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors? | British journal of pharmacology 20090101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080601 |
| Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. | The Journal of pharmacology and experimental therapeutics 20070501 |
| Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines. | Urology 20070401 |
| A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. | The Journal of urology 20030801 |
| Beta3-adrenoceptors in human detrusor muscle. | Urology 20020501 |